

Biopharmaceutical FARMING

BIOPHARMACEUTICAL FARMING



**TECHNOLOGY
CATALYSTS**

The Report

Using plants to produce biopharmaceuticals is being touted as the next generation manufacturing process for monoclonal antibodies and recombinant proteins. Growing biopharmaceuticals in plants is expected to help solve some of the current production problems facing developers. However, as with most new technologies, there are many issues to be addressed.

Plant-based biopharmaceutical manufacturing has the potential to produce large quantities of recombinant proteins or monoclonal antibodies at a lower cost than traditional mammalian cell culture. The use of plants can also avoid transmitting animal diseases by eliminating the need to extract the drugs from animals or to use animal proteins in cell culture. Also it is envisioned that it will be quicker and less expensive to scale-up (increase acreage) of a plant-based system than to build a sterile biological manufacturing facility.

However, the use of plants and especially crop plants, raises concerns about maintaining the safety of the food supply. Gene flow through pollen drift from the altered plants to plants intended for the food market is one potential transfer mechanism. Unintentional mixing during harvesting, processing, and transport is also of concern. While the proteins may be harmless if accidentally ingested, there is a major concern surrounding public reaction if contamination occurs. In addition to the safety of the human food supply, there are the possible ecological effects on animals and insects that may ingest the plants producing these proteins.

Technology Catalysts has addressed the issues raised by plant-based biopharmaceutical manufacturing in its new report *Biopharmaceutical Farming*. The report will be of benefit to companies involved in plant biotechnology and biopharmaceutical development and production. The report provides companies with insight into the issues facing the development of this technology and an understanding of the opportunities and threats for the production of biopharmaceuticals.

Table of Contents:

Introduction

Executive Summary

Plant-Derived Biologics: Technology Overview

- Introduction
- Safety and Risk Issues
- The Genetic Engineering Process
- The Three Main Categories of Plant Genetic Engineering

Regulatory Issues

- US Regulatory Stance
- European Regulatory Stance

Markets For Plant Derived Proteins

Technology Comparison

Crop Choices and Products

Technology Developers

About TCI

Technology Catalysts International, founded in 1979, is a full service strategic alliance consultancy specializing in technical and business research in pharmaceuticals, life sciences, fine chemicals, and advanced materials and processes.

Contacts are listed on the back cover for further information on the above services, or contact us on the web:

www.technology-catalysts.com

Biopharmaceutical FARMING

PURCHASE AGREEMENT

- ___ One Copy (PDF or Printed Version) \$4,950
___ Extra Copies (Either Format) \$300

We agree to limit the circulation of this report to employees of our corporation or subsidiaries and joint ventures in which our corporation holds at least a 50 percent interest.

Upon receipt of this signed Purchase Agreement, Technology Catalysts International will invoice our corporation for the purchase amount, payable upon request.

Name _____

Title _____

Company _____

Address _____

Telephone _____ Facsimile _____

E-mail _____

Signature _____ Date _____

Note: All prices are U.S. dollars

Please place a check beside the format you would like to order:

- Printed version (add \$35 for domestic shipping and \$45 for international shipping) Qty: _____
 PDF (Adobe® Acrobat, Portable Document Format)

Total Amount Due: _____

- Check enclosed, made payable to
Technology Catalysts International
- Should you wish to make a wire transfer,
please contact TCI directly

Return to:

Sandra E. Erb
Manager, Chiral & Fine Chemicals Consulting
Technology Catalysts International
605 Park Avenue
Falls Church, VA 22046, U.S.A.
Telephone: (703) 531-0247
Facsimile: (703) 237-0042
E-mail: serb@technology-catalysts.com
Internet: www.technology-catalysts.com

- Please invoice me/the company
at the above address

